box10.gif (1299 bytes)







Cardiac care

Canada joins global heart disease registry

MONTREAL CLARIFY, the largest international registry to ever be carried out in stable coronary artery disease (CAD) patients, was launched in 40 countries, including Canada, at the European Society of Cardiology (ESC) Congress.

The CLARIFY registry (ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) is designed to increase knowledge and understanding of CAD and will provide important epidemiological and clinical data, including an assessment of the role of heart rate in the prognosis of CAD patients.

Coronary artery disease remains the leading cause of death worldwide. Improved understanding of the management and outcomes of these patients is paramount to reducing the disease burden.

Data available today on the presentation and management of CAD stem mainly from randomized clinical trials or registries which have limited generalisability due to the stringent selection process of participants or the focus on a particular manifestation of the disease. There are only limited contemporary data regarding stable outpatients with CAD, their management and outcomes.

CLARIFY is a prospective, observational, longitudinal registry of stable coronary artery disease (CAD) outpatients. The registry will be representative of CAD patients seen by cardiologists and primary care physicians in daily clinical practice. A minimum of 30,000 outpatients with stable CAD from around 40 countries worldwide will be followed up for five years. Data will be collected prospectively at annual visits (12, 24, 36, 48 and 60 months). The overall aim of CLARIFY is to characterize contemporary CAD patients in terms of their demographic characteristics, clinical profiles, management and outcomes. CLARIFY will also determine long-term prognostic factors in this group of patients with a view to developing a powerful and comprehensive risk prediction model, including all potential prognostic factors, including resting heart rate. The CLARIFY registry is funded by an educational grant from Servier Research Group, an independent pharmaceutical company. Data will be collected and analyzed at the Robertson Centre for Biostatistics, Glasgow, UK, under the guidance of Prof Ian Ford, and the study is led by an executive steering committee composed of international experts in the field of CAD.

About Coronary Artery Disease
Coronary artery disease (CAD) is the most common manifestation of cardiovascular disease. It refers to the hardening and shrinking of the coronary arteries (atherosclerosis) which leads to diminished blood flow and reduces oxygen supply to the heart muscle (ischemia). The lack of oxygen supply to the heart muscle may cause angina (chest pain).

If the coronary artery becomes completely blocked, a whole section of the heart muscle is deprived of oxygen and dies, resulting in a myocardial infarction (MI) or heart attack. Coronary artery disease is a progressive, often silent disease that is most often unobserved until the first symptoms of ischemia or MI occur. Although the prognosis of patients with CAD has been greatly improved by advances in cardiovascular treatment, it is still the most frequent cause of death.

Cardiovascular disease accounts for the death of more Canadians than any other disease. In fact, in Canada someone dies every seven minutes from it. According to the latest statistics available from Statistics Canada, in 2005 cardiovascular disease accounted for close to one third of all deaths in Canada (more than 71,000 deaths).

About Servier Canada Inc.
Servier Canada Inc. ( is a pharmaceutical company, based in Laval (Quebec) that focuses on the development of therapies to treat cardiovascular, metabolic and central nervous system diseases. It is the Canadian subsidiary of the Servier Research Group, the leading French-based independent (private) pharmaceutical company, which is present in 140 countries around the world. The Servier Research Group distinguishes itself by investing 25 percent of its income in research and development, which is approximately double the industry average. This enables the advancement of scientific knowledge and the discovery of therapeutic innovations leading to improved patient care and treatment outcomes.